Oppenheimer Reiterates Perform Rating on Nordson (NDSN)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Oppenheimer Reiterates Perform Rating on Nordson (NDSN)
May 28, 2024 1:26 PM EDT
DA Davidson analyst Matthew Summerville reiterated a Buy rating and $295.00 price target on Nordson (NASDAQ: NDSN).
The analyst comments "This morning, Nordson announced an agreement to acquire publicly traded Atrion Corp. in a transaction valued at ~$800M or ~15x 2024 estimated EBITDA, inclusive of... More
May 28, 2024 7:25 AM EDT
Atrion Corporation (NASDAQ: ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million. The transaction enterprise value reflects a multiple of 20.2 times Atrions 2023 EBITDA, and the $460 per share price represents a 15% premium to Atrions 90-day average daily volume-weighted average stock price.
... More
May 28, 2024 7:00 AM EDT
Nordson Corporation (Nasdaq: NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (Nasdaq: ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrions 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. The acquisition expands Nordsons medical portfolio into new markets and therapies, supported by long-term secular growth trends.
Sundaram Nagarajan, president and chief executive officer... More
